Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 5;16(12):1884.
doi: 10.3390/v16121884.

Antiviral Stewardship in Transplantation

Sruthi Bonda  1 , Sonya Trinh  1 , Jonathan Hand  1   2
Affiliations
Review

Antiviral Stewardship in Transplantation

Sruthi Bonda et al. Viruses. .

Abstract

Though antimicrobial stewardship programs (ASPs) are required for hospitals, the involvement of transplant recipients in programmatic interventions, protocols, and metrics has historically been limited. Though there is a growing interest in studying stewardship practices in transplant patients, optimal practices have not been clearly established. A component of ASPs, antiviral stewardship (AVS), specifically targeting cytomegalovirus (CMV), has been more recently described. Understanding AVS opportunities and interventions is particularly important for transplant recipients, given the morbidity and mortality associated with viral infections, challenging clinical syndromes, ultrasensitive molecular diagnostic assays, antiviral resistance, and costs of viral disease and medications, as well as antiviral drug toxicities. This review highlights opportunities for AVS for CMV, EBV, HSV, VZV, SARS-CoV-2, respiratory syncytial virus, and BK polyomavirus in transplant patients.

Keywords: antimicrobial stewardship; antiviral stewardship; cytomegalovirus; respiratory syncytial virus.

PubMed Disclaimer

Conflict of interest statement

S.B.—none; S.T.—none; J.H. grant/research: Pfizer, Janssen, Rebiotix, Scynexis, AstraZeneca, ARLG, NIH/NIAID; Advisory Board: Pfizer, AstraZeneca, Innoviva; Honoraria: The Antibiotic Resistance Leadership Group (ARLG).

References

    1. So M., Hand J., Forrest G., Pouch S.M., Te H., Ardura M.I., Bartash R.M., Dadhania D.M., Edelman J., Ince D., et al. White paper on antimicrobial stewardship in solid organ transplant recipients. Am. J. Transplant. 2022;22:96–112. doi: 10.1111/ajt.16743. - DOI - PMC - PubMed
    1. Gyssens I.C., Kern W.V., Livermore D.M. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98:1821–1825. doi: 10.3324/haematol.2013.091769. - DOI - PMC - PubMed
    1. Jorgenson M.R., Descourouez J.L., Kleiboeker H., Goldrosen K., Schulz L., Rice J.P., Odorico J.S., Mandelbrot D.A., Smith J.A., Saddler C.M. Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard. Transpl. Infect. Dis. 2022;24:e13864. doi: 10.1111/tid.13864. - DOI - PubMed
    1. Jorgenson M.R., Descourouez J.L., Schulz L.T., Goldrosen K.A., Rice J.P., Redfield R.R., Saddler C.M., Smith J.A., Mandelbrot D.A. The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients. Infect. Control Hosp. Epidemiol. 2020;41:1068–1074. doi: 10.1017/ice.2020.203. - DOI - PubMed
    1. Dadwal S.S., Papanicolaou G.A., Boeckh M. How I prevent viral reactivation in high-risk patients. Blood. 2023;141:2062–2074. doi: 10.1182/blood.2021014676. - DOI - PMC - PubMed

Substances

LinkOut - more resources